EcoDrugPlus

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCMIG00000010365
Gene Symbol: CFTR
3 Cross references
217 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSCMIG00000008103
Gene Symbol: DNMT1
4 Cross references
212 Possible Orthologues:

Dna Topoisomerase 2-Alpha-Like

Ensembl ID : ENSCMIG00000008898
Gene Symbol: LOC103190991
2 Cross references
203 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSCMIG00000015776
Gene Symbol: TOP1
3 Cross references
274 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSCMIG00000015756
Gene Symbol: TOP2B
3 Cross references
210 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSCMIG00000004914
Gene Symbol: EML4
4 Cross references
214 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSCMIG00000007634
Gene Symbol: EPHA2
3 Cross references
125 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSCMIG00000019300
Gene Symbol: EPHA3
3 Cross references
216 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSCMIG00000015022
Gene Symbol: FYN
4 Cross references
264 Possible Orthologues:

G Protein-Coupled Receptor 42

Ensembl ID : ENSCMIG00000015473
Gene Symbol: GPR42
1 Cross references
663 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSCMIG00000016921
Gene Symbol: HCK
4 Cross references
206 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSCMIG00000006386
Gene Symbol: ITK
4 Cross references
208 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).